Ion; 2011.doi:ten.11861475-2875-12-450 Cite this short article as: Quashie et
Ion; 2011.doi:10.11861475-2875-12-450 Cite this article as: Quashie et al.: A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs. Malaria Journal 2013 12:450.Submit your subsequent manuscript to BioMed Central and take full advantage of:Practical on-line submission Thorough peer overview No space constraints or color figure charges Instant publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Investigation which can be freely readily available for redistributionSubmit your manuscript at biomedcentralsubmit
HIPPOKRATIA 2013, 17, two:187-CASE REPORTBleomycin cardiotoxicity through chemotherapy for an ovarian germ cell tumorDidagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C1st Division of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, Thessaloniki, GreeceAbstract Introduction: IDO2 drug Platinum-based chemotherapeutic regimens, such as BEP (bleomycin, etoposide, cisplatin) represent the common of care, first line therapy in non-epithelial ovarian tumours. Cardiovascular toxicity is really a rare DP medchemexpress adverse effect of bleomycin. Case Report: A 41-year-old lady with ovarian granulosa tumor, treated with 1st line BEP chemotherapy experienced chest discomfort rapidly progressing to serious precordial discomfort in the course of bleomycin infusion. The infusion was stopped and electrocardiographic changes indicative of myocardial ischemia had been revealed. Anti-anginal and anti-thrombotic remedy was introduced. Cardiac enzymes were not elevated and echocardiographic findings showed no wall motion abnormalities. Twenty four hours right after the episode the elctrocardiographic changes insisted and chemotherapy was decided to become continued, excluding bleomycin, with no symptom recurrence. Discussion: Cardiovascular complications pose a uncommon but prospective fatal adverse impact of BEP chemotherapy and should be meticulously addressed, specially in sufferers with extra cardiovascular danger variables. Physicians coping with bleomycin-based therapies may perhaps find this know-how helpful to get a a lot more comprehensive evaluation of chest discomfort syndromes in these patients. Hippokratia 2013, 17, two: 1787-188 Keyword phrases: BEP chemotherapy, ovarian cancer, cardiotoxicity, myocardial ischemia, chest painCorresponding Author: Anastasios Boutis, 1st Department of Clinical Oncology-Chemotherapy, Theagenio Cancer Hospital, 54007, Thessaloniki, Greece, tel.: 302310898711, 306937040299, fax:302310845514, e-mail: alboutisotenet.grIntroduction BEP (bleomycin, etoposide, cisplatin) chemotherapeutic regimen represents the regular of care 1st line therapy in non-epithelial ovarian tumours1. Cardiovascular toxicity is a uncommon adverse impact of bleomycin and may be expressed clinically as hypotension, pericarditis, acute substernal chest pain, coronary artery disease, myocardial ischemia, myocardial infarction, cerebral vascular accident and Raynaud’s phenomenon2. Case report A 41-year-old lady with sophisticated recurrent ovarian cancer (adult granulosa cell tumor, initial stage pT2b pN1 M0, FIGO IIIC, 4 years just before) was treated with 1st line platinum-based chemotherapy. Pre-treatment cardiovascular risk components incorporated arterial hypertension (properly controlled with angiotensin II receptor blockers) and obesity (BMI: 40.3 Kgm2). Baseline cardiologic evaluation with ECG and echocardiogram just before initiation of chemotherapy was unremarkable. For the duration of the first cycle of therapy and in the course of the bleomycin infusion, ch.
